Accueil   Diary - News   All news IXALTIS announces successful completion of phase 2 for its compound Litoxtine

IXALTIS announces successful completion of phase 2 for its compound Litoxtine

 

 

Toulouse (31) /Archamps (74), May, 14th, 2019 – Ixaltis is pleased to announce successful completion of the phase 2 of clinical development in urinary incontinence for its lead compound Litoxetine. Litoxetine is an SSRI (Selective Serotonin Reuptake Inhibitor) and serotonin agonist-antagonist with specific activities on some receptor subtypes. The positivie results pave the way to progress to phase 3 for this compound with the potential of being "first in class" for treating mixed urinary incontinence, a disease for which there is no appoved medical treatment on the market.

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree